Brinzolamide

CAS No. 138890-62-7

Brinzolamide( AL 4862 | Azopt )

Catalog No. M11614 CAS No. 138890-62-7

Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
10MG 29 In Stock
25MG 55 In Stock
50MG 83 In Stock
100MG 121 In Stock
200MG Get Quote In Stock
500MG 253 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Brinzolamide
  • Note
    Research use only, not for human use.
  • Brief Description
    Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor.
  • Description
    Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor. Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II). Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure. Brinzolamide is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. (In Vivo):Brinzolamide (7.5 mg or 12 mg) implanted in a silicone matrix is extremely well tolerated and provides sustained release of brinzolamide and significant reduction in intraocular pressure (IOP) for up to 28 days with no adverse effects or signs of toxicity in normotensive NZW rabbits.
  • In Vitro
    ——
  • In Vivo
    Brinzolamide (7.5 mg or 12 mg) implanted in a silicone matrix is extremely well tolerated and provides sustained release of brinzolamide and significant reduction in intraocular pressure (IOP) for up to 28 days with no adverse effects or signs of toxicity in normotensive NZW rabbits.The pharmacokinetic parameters of Brinzolamide in rabbits.Animal Model:Rabbits Dosage:7.5 mg, 12 mg Administration:Brinzolamide silicone matrix implant placed in the episcleral space Result:Resulted in a significant IOP reduction of 4.6 mmHg on days 10-28, with concentrations of 12 mg.
  • Synonyms
    AL 4862 | Azopt
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Carbonic Anhydrase
  • Recptor
    Carbonic anhydrase II
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    138890-62-7
  • Formula Weight
    383.51
  • Molecular Formula
    C12H21N3O5S3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 77 mg/mL (200.77 mM)
  • SMILES
    CCN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Stams T, et al. Protein Sci. 1998 Mar;7(3):556-63.
molnova catalog
related products
  • Compound CDy9

    Compound CDy9 is a highly selective inhibitor of carbonic anhydrase (CA) with an IC50 value of 0.18 μM for hCA II.

  • EMAC10101d

    compound EMAC10101d, bearing a 2,4-dichorophenyl substituent in position 4 of the dihydrothiazole ring, was the most potent and selective toward hCA II with an inhibitory activity in the low nanomolar range.

  • Disulfamide

    Disulfamide is an orally active carbonic anhydrase inhibitor with an IC50 value of 0.07 μM. Disulfamide has a diuretic effect by inhibiting carbonic anhydrase and preventing the reabsorption of sodium and bicarbonate in the proximal convoluted tubules.